BIOTECH100
A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Pipeline Drugs 

Biotechnology Encyclopedia

Vaccine -- Vaccination

A bottle and a  containing the  vaccine. A vaccine (named after vaccinia, the infectious agent of cowpox, which, when vaccinated, provides protection against smallpox) is used to prepare a human or animal's immune system to defend the body against a specific pathogen, usually a bacterium, a virus or a toxin. Depending on the infectious agent to prepare against, the vaccine can be a weakened bacterium or virus that lost its virulence, or a toxoid (a modified, weakened toxin or particle from the infectious agent). The act of vaccinating members of the population is also known as inoculation, though inoculation can mean use of the live pathogen itself.
A bottle and a syringe containing the influenza vaccine.  

Developing immunity

The immune system recognizes the vaccine particles as foreign, destroys them and "remembers" them. When the virulent version of the agent comes along, the immune system is prepared for a fast strike, neutralizing the agent before it can spread and multiply to vast numbers.

Live but weakened vaccines are used against tuberculosis, rabies, and smallpox; killed agents are used against cholera and typhoid; toxoids against diphtheria and tetanus.

Vaccines, though they are by far not as virulent as the "real" agent, can have unpleasant side effects, and have to be renewed every few years. A new attempt to avoid these obstacles of "classic" vaccination is DNA vaccination. The DNA coding for a part of a virus or a bacterium that is recognizable by the immune system is inserted and expressed in human/animal cells. These cells now produce the toxoid for the infectious agent, without the effects other parts of a weakened agent might have. As of 2003, DNA vaccination is still experimental, but shows some promising results.

Disease eradication

Many diseases such as polio have been largely controlled in developed nations through mass use of vaccines (indeed, smallpox appears to have been completely eliminated in the wild).

As long as the vast majority of people are vaccinated it is difficult for an outbreak of disease to spread. This effect is called herd immunity. Some people, particularly those who practice alternative medicine, refuse to immunize themselves or their children, as they believe vaccines' side effects outweigh their benefits, or that not enough is known of the long-term adverse effects to determine whether the harm is smaller than the benefit. Thus, they reap some of the benefits of vaccines, through herd immunity, without assuming any of the risks. Advocates of routine vaccination argue that side effects of approved vaccines, whilst real, are either far, far less serious than actually catching the disease, or are very rare, and argue that the calculus of risk/benefit ratio should be based on benefit to humanity rather than simply on the benefit to the immunized individual. The main risk of rubella, for example, is to the fetuses of pregnant women, but this risk can be effectively reduced by the immunization of children to prevent transmission to pregnant women.

Smallpox

Vaccination against smallpox seems especially contentious. Dissenters falsely suggest that modern vaccines might result in outbreaks of smallpox (in fact, they contain no smallpox virus: they contain live vaccinia virus), and suggest that infections in the past originated (as in the small vaccinia outbreak in England in 1961), spread in greater proportion, and/or were more lethal amongst the vaccinated. They contend that improved sanitation and nutrition, not vaccine, account for most of the reduction in smallpox. Inoculation proponents dispute these allegations, and recognize that the current vaccine has risks. As the risk of the disease (barring germ warfare) is effectively zero, routine smallpox vaccination has not been recommended for many years.

The threat from smallpox as a biological weapon has however, caused a reconsideration, though not a reversal, of this position. A 2003 US vaccination effort was unpopular. There was poor turnout among hospital staff who were designated to be the first to receive the vaccine. In addition to the known risks of the vaccine, several deaths were reported from cardiac causes among the immunized, suggesting that people with coronary artery disease might be at risk. Development of newer formulations that might avoid the newly discovered risks is underway. Illinois and New York suspended the program pending investigation of the apparent vaccine deaths of two healthcare workers (the main focus of the program). The California Nurses Association opposed the effort from the start.[1] (http://rense.com/general36/poxx.htm)[2] (http://www.usatoday.com/news/health/2003-10-15-smallpox_x.htm)

Autism controversy

In the late 1990s, vaccines became the target of controversy when a link to autism was suggested.

Some groups in the United States claimed a link due to a preservative called thimerosal. Thimerosal is a preservative that contains mercury. It was (and in some cases still is) used in some DTP (diphtheria, tetanus and pertussis) vaccine formulations. In sufficient quantities, mercury has deleterious neurological effects, and thus it is tightly regulated (in the United States, this regulation is supervised by the EPA). DTP vaccines are routinely administered to children under the age of 2 in developed nations, so most children in these nations have been exposed to thimerosal through vaccination. In 1999, the FDA re-evaluated (http://www.fda.gov/cber/vaccine/thimerosal.htm) the risk of using thimerosal in vaccine products under the 1997 FDA Modernization Act. In its report of October 1, 2001, the Institute of Medicine's Immunization Safety Review Committee concluded that the evidence is inadequate to either accept or reject a causal relationship between thimerosal exposure from childhood vaccines and autism. In a further report, of May 2004 [3] (http://www.iom.edu/report.asp?id=20155) the institute said that epidemiological evidence favored rejection of any link between thiomerosal-containing vaccines and autism.

A second, parallel, controversy arose in the United Kingdom over the vaccine for measles, mumps, and rubella (MMR), another vaccine that is routinely administered to children under the age of 2 in developed nations, but which contains no preservative. A claimed possible link to autism came to the forefront when in 1998, Wakefield and colleagues (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9500320) reviewed reports of children with bowel symptoms and regressive developmental disorders, mostly autism, in a small sample of 12 children. The study had weaknesses such as small sample size, and no use of healthy controls. In 2004, 10 of the 13 authors of the original Wakefield study retracted the paper's interpretation, stating that the data were insufficient to establish a causal link between MMR vaccine and autism. This followed an investigation by Brian Deer for the London Sunday Times, who reported that Wakefield had links to lawyers hoping to sue the vaccines' manufacturers [4] (http://briandeer.com/mmr-lancet.htm). Further allegations were made by Deer in a UK television documentary, MMR: What They Didn't Tell You, first broadcast in November 2004 [5] (http://briandeer.com/wakefield-deer.htm).

The Wakefield study garnered media attention and caused concern in the minds of many parents leading to a drop in the uptake of the MMR vaccine in the UK and some other countries.

In response to the US and UK controversies, which closely mirror the framing of litigation in the two countries, a number of studies with large sample sizes were researched in many developed nations. The vast majority of those studies showed no correlation between the use of vaccines (including the MMR vaccine) and increased autism: -

The autism controversy highlighted several issues pertaining to public health, biological science, ethical standards, and the medical community. First, it stresses the value of large-scale, case-controlled scientific studies in proving or disproving a hypothesis (in this case, a link between autism and vaccines). Secondly, it shows both the importance of medical professionals having the most solid and up-to-date information and the importance of communicating this information in a clear and unbiased fashion to patients. Thirdly, it highlighted the changing role of the medical community from authoritarian wardens to counsellors who provide informed choices, as well as the evolution of the doctor-patient relationship as a partnership. Lastly, it emphasized that current medical issues involve all aspects of modern culture and society, including the media, the affected families, and the scientific community at large.

 
Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
 Biotech100 list of companies
Pipeline drugs for the Biotech100


Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index


Sponsored Links


Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?

Key Biotech Terms


Google
 
Web www.biotech100.com
SEARCH THE BIOTECH100 WEBSITE
  
     

 
All text is available under the terms of the GNU Free Documentation License (see Copyrights for details). Disclaimers. Wikipedia is powered by MediaWiki, an open source wiki engine..
 


Copyright 2005 BIOTECH100.COM. All rights reserved.

email: info@biotech100.com